You are here

Clinical Trials: Cord Blood

Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Juvenile Myelomonocytic Leukemia
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: GVHD Prophylaxis;   Drug: Gemtuzumab Ozogamicin;   Drug: Anti-Thymocyte Globulin;   Drug: Isotretinoin
Sponsor:   Columbia University
Active, not recruiting - verified July 2017
Condition:   Severe Thalassemia
Intervention:   Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
Sponsors:   Washington University School of Medicine;   New England Research Institutes;   Pediatric Blood and Marrow Transplant Consortium
Unknown status
Conditions:   Leukemia;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   MDS;   Multiple Myeloma
Interventions:   Drug: EPOCH-F/R;   Drug: FLAG;   Drug: Transplant Preparative Regimen (Flu/Cy/Mes);   Drug: GVHD Prophylaxis (tacrolimus and sirolimus);   Procedure: Double Cord Blood Transplantation
Sponsor:   National Cancer Institute (NCI)
Terminated - verified May 20, 2013
Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndromes
Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: Total body irradiation;   Biological: Umbilical cord blood unit with C3a fragment;   Biological: Unmanipulated UCB Unit
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Heart, Lung, and Blood Institute (NHLBI)
Conditions:   Sickle Cell Disease;   Thalassemia;   Diamond-Blackfan Anemia
Interventions:   Procedure: Bone marrow transplantation;   Biological: Mesenchymal Stromal Cells
Sponsors:   Stanford University;   University of Minnesota - Clinical and Translational Science Institute;   University of Alabama at Birmingham
Condition:   Congenital Pediatric Disorders
Interventions:   Drug: Busulfan;   Drug: Cytoxan;   Drug: Fludarabine;   Procedure: Cord Blood Stem Cell Infusion
Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital
Recruiting - verified September 2017
Conditions:   Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma;   Lymphoma
Interventions:   Drug: Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG);   Procedure: Stem Cell Transplant;   Procedure: Stem Cells Collections;   Drug: Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI);   Drug: Fludarabine, Busulfan, and ATG
Sponsor:   University of Chicago
Active, not recruiting - verified July 2017
Conditions:   MDS;   Immunodeficiency;   GATA2
Interventions:   Drug: Cyclophosphamide (CTX, Cytoxan);   Drug: Fludarabine(Fludara,Berlex Laboratories);   Procedure: Total Body Irradiation (TBI);   Procedure: Allogeneic HSC;   Drug: Equine Anti-Thymocyte Globulin
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting
Condition:   Non-Malignant
Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   medac GmbH;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2017
Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
Intervention:   Drug: CPX-351
Sponsors:   Weill Medical College of Cornell University;   Jazz Pharmaceuticals
Active, not recruiting